IQN Path is pleased to announce and endorse two new CBQAReadout modules including VENTANA PD-L1 (SP142) Assay, NSCLC, atezolizumab (3 hours) and VENTANA PD-L1 (SP263) Assay, NSCLC, nivolumab (3 hours).
VENTANA PD-L1 (SP142) Assay, triple negative breast cancer, atezolizumab and nab-paclitaxel (2 hours) module will be open on June 1st, 2020.
We will update you regularly about the new CBQAReadout.ca modules.
For your interest, CBQAReadout.ca is now also developing FISH readout modules as well as additional IHC modules (e.g. ER, PR, HER2 for breast cancer, HER2 for gastric cancer, and MMR for colon cancer).
Please note that the SP263 module uses the so-called “Cologne Score” with multiple cut-off TPS points
for various different purposes and is ideal for training and sharpening pathologists’ skills in TPS
estimation.
AVAILABLE MODULES:
1. IMMUNOTHERAPY – PD-L1 IHC Biomarkers: PD-L1 IHC 22C3 pharmDx, NSCLC, pembrolizumab (2
hours)
2. TARGETED THERAPY IHC Biomarkers: ALK IHC (LDT, 5A4 OR D5F3), Non-squamous NSCLC
(nsNSCLC), crizotinib (1 hour)
3. TARGETED THERAPY IHC Biomarkers: VENTANA ALK (D5F3) Assay, Non-squamous NSCLC
(nsNSCLC), crizotinib 1 hour)
4. TARGETED THERAPY IHC Biomarkers: ROS1 IHC (LDT, D4D6), Non-squamous NSCLC (nsNSCLC),
crizotinib (2 hours)
5. IMMUNOTHERAPY – PD-L1 IHC Biomarkers: VENTANA PD-L1 (SP142) Assay, NSCLC, atezolizumab
(3 hours) NEW
6. IMMUNOTHERAPY – PD-L1 IHC Biomarkers: VENTANA PD-L1 (SP263) Assay, NSCLC, nivolumab (3
hours) NEW
7. IMMUNOTHERAPY – PD-L1 IHC Biomarkers: VENTANA PD-L1 (SP142) Assay, triple negative
breast cancer, atezolizumab and nab-paclitaxel (2 hours) STARTING JUNE 1 ST , 2020